Although there are several paired organ systems in the body, the eyes are unique in that many ocular diseases can affect either one or both eyes and many treatments are delivered ocularly, not systemically. These unique traits allow each eye to be tested and treated independently when evaluating a new treatment delivered ocularly. Since more data are generally better, why do the majority of ophthalmology clinical trials limit enrollment to 1 eye per participant ignoring the opportunity to efficiently collect more information?1
Glassman AR, Melia M. Randomizing 1 Eye or 2 Eyes: A Missed Opportunity. JAMA Ophthalmol. 2015;133(1):9–10. doi:10.1001/jamaophthalmol.2014.3600
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: